Stock GILDGILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2025-04-22 pm EDT 		5-day change 1st Jan Change
105.51 USD +1.13% Intraday chart for Gilead Sciences, Inc. -0.93% +14.23%
Apr. 21 Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study MT
Apr. 21 Gilead Sciences Sees Positive Results in Phase 3 Study of Aggressive Breast Cancer DJ

Press Releases

Search
See the results
Gilead Sciences - Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients with Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
Apr. 22
 AQ
Biomedical HIV Prevention Summit in Atlanta Is the Focus To Drive Meaningful Action With Gilead Sciences
Apr. 22
 AQ
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
Apr. 21
 BU
Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program
Apr. 15
 AQ
Gilead Sciences : First Quarter 2025 Estimated Acquired IPR&D
Apr. 10
 PU
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
Apr. 10
 BU
PatientView Ranks Gilead "Best" at ESG
Apr. 10
 AQ
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections
Apr. 08
 AQ
Discovering a Breakthrough: Gilead's Long-Standing Commitment to Helping Change the Course of HIV
Apr. 01
 AQ
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer
Mar. 25
 AQ
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies
Mar. 18
 AQ
Gilead Sciences - Women's History Month Celebrated With Its Team
Mar. 14
 AQ
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Mar. 12
 AQ
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Mar. 12
 BU
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Mar. 11
 BU
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
Feb. 24
 BU
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Feb. 20
 BU
Gilead Sciences to Present at Upcoming Investor Conferences
Feb. 19
 BU
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease
Feb. 19
 AQ
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Feb. 18
 BU
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC
Feb. 14
 AQ
Gilead Sciences : Fourth Quarter 2024 Resource Book
Feb. 11
 PU
Gilead Sciences : Fourth Quarter 2024 Prepared Remarks
Feb. 11
 PU
Gilead Sciences : Fourth Quarter 2024 Summary of Remarks
Feb. 11
 PU
Gilead Sciences : Fourth Quarter 2024 Supplementary Information
Feb. 11
 PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Press Releases